Fisher Asset Management Increases Eli Lilly Stake to 4.45M Shares

Fisher Asset Management's recent filing reveals a strategic accumulation of Eli Lilly (LLY) stock, a move that underscores the sustained institutional appetite for dominant players in the metabolic and oncology spaces. By adding 150,595 shares, Fisher has solidified its position as a significant stakeholder, now holding over 4.45 million shares. This 3.5% increase in the third quarter reflects a "buy-and-hold" conviction in Lilly’s long-term value proposition, particularly as the company continues to lead the high-growth GLP-1 market. The timing of this acquisition is notable, as it occurred during a period where market volatility has led some investors to rotate out of high-growth names. Fisher’s decision to double down suggests a belief that Lilly’s fundamentals remain decoupled from broader macroeconomic headwinds.

Eli Lilly has transformed from a traditional pharmaceutical powerhouse into a market leader in obesity and diabetes care. The success of Mounjaro and Zepbound has not only driven record revenues but has also fundamentally shifted investor expectations for the entire healthcare sector. Institutional investors like Fisher Asset Management are likely looking past short-term volatility to the massive total addressable market (TAM) for weight-loss medications, which some analysts project could exceed $100 billion by 2030. The company's ability to maintain its competitive edge against rivals like Novo Nordisk will be a key driver of future performance, and this increased stake suggests that Fisher believes Lilly is well-positioned to capture a significant portion of that market. Furthermore, Lilly’s robust R&D spending, which consistently outpaces many of its peers, ensures that its pipeline remains stocked with potential blockbusters beyond its current metabolic portfolio.

“

Institutional investors like Fisher Asset Management are likely looking past short-term volatility to the massive total addressable market (TAM) for weight-loss medications, which some analysts project could exceed $100 billion by 2030.

This accumulation suggests that large-scale asset managers view Lilly's current valuation as attractive relative to its future earnings potential. While the stock has seen significant appreciation over the past two years, the continued expansion of manufacturing capacity and the development of next-generation oral GLP-1s provide a clear roadmap for growth. Furthermore, Lilly’s pipeline in Alzheimer’s disease, specifically with the progress of donanemab, adds a secondary layer of diversification that appeals to institutional risk profiles. The company's focus on high-impact therapeutic areas ensures a steady stream of potential catalysts that can drive share price appreciation over the coming years. Investors are also closely watching the company’s expansion into immunology and gene therapy, which could provide the next leg of growth as the metabolic market eventually matures.